Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Mus musculus, mouse |
| Cell Line Description | RM-1 (also known as RM1) is a conditionally transformed murine prostate cancer cell line established in 1994 by T.C. Thompson and his colleagues. This cell line was derived from urogenital sinus cells of 17-day-old male C57BL/6 mouse embryos. Researchers transduced these embryonic cells with the Zipras/myc9 recombinant retrovirus—which carries the v-Ha-ras and v-myc oncogenes—and subsequently transplanted them beneath the renal capsules of adult syngeneic male mice. The RM-1 cell line was established from the resulting poorly differentiated carcinomas once they had developed. Characterized by its aggressive proliferative capacity and high metastatic potential, the RM-1 cell line has emerged as the preferred syngeneic immunocompetent murine model globally for investigating the pathobiology of prostate cancer, androgen sensitivity, tumor immunology, and novel immunotherapeutic interventions. |
| Tissue | Prostate; Urogenital sinus |
| Disease | Carcinoma of the mouse prostate gland (Prostate Cancer) |
| Morphology | Fibroblast-like; grows as an adherent monolayer |
| Gender | Male |
| Age | 17-day-old fetus (17FD) |
| Product Format | Frozen |
| Growth Mode | Adherent |
| Biosafety Level | 1 (Contains integrated, non-infectious recombinant retroviral fragments encoding v-Ha-ras and v-myc) |
| Applications | 1. Establish a syngeneic mouse model of prostate cancer growth, local invasion, and metastasis in immunocompetent C57BL/6 mice. 2. Investigate the dynamic changes in androgen receptor (AR) expression and the mechanisms driving androgen insensitivity. 3. Characterize the components of the tumor immune microenvironment and evaluate immune checkpoint blockade therapies. 4. Conduct preclinical efficacy screening for novel chemotherapeutic compounds and targeted anti-tumor agents. 5. Perform in vivo evaluation of cancer vaccines and gene therapy vectors. |
| Shipped In | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Tumorigenic | Yes, highly tumorigenic and metastatic in isogenic C57BL/6 and immunocompromised mice |
| Origin Markers | Expresses cytokeratin 18 mRNA and reacts with cytokeratin-specific antiserum, confirming its epithelial/urogenital tissue lineage. |
| Androgen Response | It maintains functional androgen receptors (AR) and, when exposed to testosterone under serum-free conditions, exhibits a significant acceleration in mitogenic growth (approximately a two-fold increase). |
| Oncogenes | Formally carries and expresses transformed v-Ha-ras and v-myc oncogenes driving its malignant phenotype. |
| Growth Kinetics | It possesses extremely strong proliferative capacity; cell density should be actively maintained between 2 X 10^4 and 4 X 10^5 cells/cm2. |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. Remove and discard the spent culture medium. 2. Gently rinse the adherent cell monolayer with Dulbecco's Phosphate-Buffered Saline (DPBS) to remove residual traces of serum containing trypsin inhibitors. 3. Add 2.0 to 3.0 mL of 0.25% Trypsin–0.53 mM EDTA solution to the culture flask. 4. Incubate at 37°C for 5 to 15 minutes. Observe under an inverted microscope until the cell layer detaches and disperses. Note: Avoid mechanical agitation (tapping or shaking the flask) to prevent cell clumping. 5. Add an equal or greater volume of complete culture medium to neutralize the trypsin activity. 6. Centrifuge the cell suspension at 150-300 × g for 7 minutes; aspirate the supernatant, gently resuspend the cell pellet in fresh medium, and then seed into new culture dishes. |
| Medium Renewal | 2 to 3 times per week |
| Subcultivation Ratio | A split ratio of 1:8 to 1:10 is standardly recommended due to its rapid proliferation. |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | 90% Complete growth medium + 10% DMSO (or 50% RPMI 1640 + 40% FBS + 10% DMSO) |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RH0193M | Humanized FOLH1 Murine Tumor Cell Line | Inquiry |
| CSC-RO01218 | Cas9 Stable Cell Line - RM-1 | Inquiry |
| CSC-RR00708 | Luciferase Reporter Cell Line - RM-1 | Inquiry |
| CSC-RO01643 | OVAL Stable Cell Line - RM-1 | Inquiry |
| CSC-RO01896 | GFP/OVAL Stable Cell Line - RM-1 | Inquiry |
| CSC-RO02149 | Luc/OVAL Stable Cell Line - RM-1 | Inquiry |
| CSC-RO02402 | GFP/Luc/OVAL Stable Cell Line - RM-1 | Inquiry |
| CSC-RR00976 | GFP/Luc Reporter Cell Line - RM-1 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.